PJP News and Press, Invesco Dynamic Pharmaceuticals From 06/21/22

Invesco Dynamic Pharmaceuticals ETF (PJP) - $0.2067. 30-Day SEC Yield of 0.89% as of June 17. Payable Jun 30; for shareholders of record Jun 22; ex-div Jun 21. For further details see: Invesco Dynamic Pharmaceuticals ETF declares quarterly distribution of $0.2067

Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This report optimizes tradi...

How similar will the next three or five years look from the years that immediately preceded the pandemic? And what are the implications for us as global equity investors? We don’t expect anything like the hyperinflation and stagflation we experienced in the 1970s; our outlook s...

With the world facing inflationary and geopolitical hurdles, economic growth is poised to slow. Shares across sectors have been hit hard. Investors in growth stocks must identify companies with the right features to overcome headwinds to earnings. For further details see: ...

Bausch Health has seen a very tough 2022 as investors price in higher interest rates on its massive debt load and softer IPO of its subsidiary Bausch + Lomb. These are not encouraging trends, but the valuation reset has been enormous, potentially creating an opportunistic investment o...

Healthcare, Staples, and Utilities continue to outperform as selling intensifies in the growth style. Investor positioning is still light in the space – even after a year of alpha. While absolute valuations have turned somewhat pricey, the defensive supersector shows decent...

AbbVie is a very high-quality company with strong cash flows, exactly the type of company you want to own if we fall into a recession. But it recently posted disappointing results that caused a selloff. Despite near-term pain, the long-term thesis remains strong. For further...

During the last Fed rate raising cycle, it took the Federal Reserve five years to raise the fed funds rate to 2.50%. The Fed kept rates far too low for far too long and now we are dealing with the consequences. Both fiscal and monetary policy have been highly inflationary, and we are ...

AbbVie reported Q122 earnings last night, and there was good and bad news - the bad led to a share price drop of ~10%. Revenues came in a little lower than Street expectations, at $13.54bn, and FY22 EPS was downgraded from $14.00 - $14.20 to $13.92 - $14.12. Nevertheless, forward ...

Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This report optimizes tradi...